Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

Curigliano G. et al, (2023), Br J Cancer, 128

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

Taylor CA. et al, (2022), Nat Med

A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.

Curigliano G. et al, (2022), Br J Cancer

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Horgan D. et al, (2022), Healthcare (Basel), 10

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

Larkin J. et al, (2022), Eur J Cancer, 173, 285 - 296

Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes.

Garg M. et al, (2022), Nat Commun, 13

VCAM-1-targeted magnetic resonance imaging improves detection of the tumor-brain interface.

Cheng VWT. et al, (2022), Clin Cancer Res

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.

Weber JS. et al, (2021), Eur J Cancer

Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity.

Watson RA. et al, (2021), Sci Immunol, 6

Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer

SIVAKUMAR S. et al, (2021), Molecular Biomarkers and Precision Medicine for Pancreatic, Liver and Biliary Tract Cancers

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

Dalle S. et al, (2021), BMC Cancer

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

Dalle S. et al, (2021), BMC Cancer

Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.

Ye W. et al, (2021), Br J Cancer

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Garg M. et al, (2021), Nature Communications

sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.

Fane ME. et al, (2020), Clin Cancer Res

Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma.

Middleton MR. et al, (2020), Clin Cancer Res

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.

Middleton MR. et al, (2020), Br J Cancer

Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?

Cheung VTF. et al, (2020), Br J Cancer, 123, 207 - 215

Immune responses in pancreatic cancer may be restricted by prevalence of activated regulatory T-cells, dysfunctional CD8+ T-cells, and senescent T-cells

Sivakumar S. et al, (2020), Biorxiv

ctDNA monitoring using patient-specific sequencing and integration of variant reads.

Wan JCM. et al, (2020), Sci Transl Med, 12

Load More

1
2
3
4
5
6
7
...
»